RT Journal Article SR Electronic T1 Comparative Effects of the Administration Period of Adjuvant Chemotherapy using Doxifluridine (5'-DFUR) for 1 Year Versus 3 Years after Breast Cancer Surgery by the Shimane Breast Cancer Study Group JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 591 OP 597 VO 26 IS 1B A1 SHIMANE BREAST CANCER STUDY GROUP, JAPAN YR 2006 UL http://ar.iiarjournals.org/content/26/1B/591.abstract AB Background: The present study investigated the efficacy of oral doxifluridine (5'-DFUR) by comparing the survival between patients who received 5'-DFUR at 800 mg/body daily for 1 or 3 years after surgery for stage 1, 2 or 3 breast cancer. Patients and Methods: Ninety-two patients were enrolled from January 1995 to December 1997, of whom 87 were eligible. The patients were stratified into pre-menopausal and post-menopausal groups, and then each group was further stratified into 1-year or 3-year administration groups. All patients were given endocrine therapy, with gosereline acetate (3.6 mg/body, monthly) for the pre-menopausal patients and tamoxifen (20 mg/day, daily) for the post-menopausal patients for 3 years. Results: The median follow-up duration was 9.5 years. Although no differences were found in the overall or disease-free survivals between the administration groups, subset analysis demonstrated that, in the pre-menopausal patients, the 3-year administration group showed a significantly higher overall survival rate than the 1-year administration group, but not in post-menopausal patients. A multivariate analysis also indicated that the administration duration of 5'-DFUR was a significant factor for disease-free survival. Conclusion: The present study supports the usefulness of 5'-DFUR for adjuvant chemotherapy against breast cancer, especially for pre-menopausal patients; however, further clinical study with a much larger sample size is necessary to reach a conclusive result. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved